Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.
2.

Checkpoint inhibitors in hematological malignancies.

Ok CY, Young KH.

J Hematol Oncol. 2017 May 8;10(1):103. doi: 10.1186/s13045-017-0474-3. Review.

3.

Immunometabolic Regulations Mediated by Coinhibitory Receptors and Their Impact on T Cell Immune Responses.

Patsoukis N, Weaver JD, Strauss L, Herbel C, Seth P, Boussiotis VA.

Front Immunol. 2017 Apr 11;8:330. doi: 10.3389/fimmu.2017.00330. eCollection 2017. Review.

4.

Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma.

Moy JD, Moskovitz JM, Ferris RL.

Eur J Cancer. 2017 May;76:152-166. doi: 10.1016/j.ejca.2016.12.035. Epub 2017 Mar 18. Review.

PMID:
28324750
5.

The T cell IFT20 interactome reveals new players in immune synapse assembly.

Galgano D, Onnis A, Pappalardo E, Galvagni F, Acuto O, Baldari CT.

J Cell Sci. 2017 Mar 15;130(6):1110-1121. doi: 10.1242/jcs.200006. Epub 2017 Feb 2.

PMID:
28154159
6.

Melanoma immunotherapy dominates the field.

Diamantopoulos P, Gogas H.

Ann Transl Med. 2016 Jul;4(14):269. doi: 10.21037/atm.2016.06.32. Review.

7.

CD28 co-stimulation in T-cell homeostasis: a recent perspective.

Beyersdorf N, Kerkau T, Hünig T.

Immunotargets Ther. 2015 May 28;4:111-22. doi: 10.2147/ITT.S61647. eCollection 2015. Review.

8.

Checkpoint Inhibitors and Their Application in Breast Cancer.

Bedognetti D, Maccalli C, Bader SB, Marincola FM, Seliger B.

Breast Care (Basel). 2016 Apr;11(2):108-15. doi: 10.1159/000445335. Epub 2016 Apr 26. Review.

9.

Reversing T-cell Dysfunction and Exhaustion in Cancer.

Zarour HM.

Clin Cancer Res. 2016 Apr 15;22(8):1856-64. doi: 10.1158/1078-0432.CCR-15-1849. Review.

10.

Control of T cell antigen reactivity via programmed TCR downregulation.

Gallegos AM, Xiong H, Leiner IM, Sušac B, Glickman MS, Pamer EG, van Heijst JW.

Nat Immunol. 2016 Apr;17(4):379-86. doi: 10.1038/ni.3386. Epub 2016 Feb 22.

11.

Cell Type-Specific Regulation of Immunological Synapse Dynamics by B7 Ligand Recognition.

Brzostek J, Gascoigne NR, Rybakin V.

Front Immunol. 2016 Feb 4;7:24. doi: 10.3389/fimmu.2016.00024. eCollection 2016. Review.

12.

Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?

Ryan JM, Wasser JS, Adler AJ, Vella AT.

Expert Opin Biol Ther. 2016;16(5):655-74. doi: 10.1517/14712598.2016.1152256. Epub 2016 Feb 25. Review.

13.

Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors.

Rajani KR, Vile RG.

Viruses. 2015 Nov 13;7(11):5889-901. doi: 10.3390/v7112914. Review.

14.

CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition.

Buchbinder EI, Desai A.

Am J Clin Oncol. 2016 Feb;39(1):98-106. doi: 10.1097/COC.0000000000000239. Review.

15.

New developments in the management of advanced melanoma - role of pembrolizumab.

Improta G, Leone I, Donia M, Gieri S, Pelosi G, Fraggetta F.

Onco Targets Ther. 2015 Sep 14;8:2535-43. doi: 10.2147/OTT.S72823. eCollection 2015. Review.

16.

Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade.

Buchbinder E, Hodi FS.

J Clin Invest. 2015 Sep;125(9):3377-83. doi: 10.1172/JCI80012. Epub 2015 Sep 1. Review.

17.

Narrowing the Gap: Preserving Repertoire Diversity Despite Clonal Selection during the CD4 T Cell Response.

Merkenschlager J, Kassiotis G.

Front Immunol. 2015 Aug 11;6:413. doi: 10.3389/fimmu.2015.00413. eCollection 2015. Review.

18.

Vitamin D Antagonises the Suppressive Effect of Inflammatory Cytokines on CTLA-4 Expression and Regulatory Function.

Jeffery LE, Qureshi OS, Gardner D, Hou TZ, Briggs Z, Soskic B, Baker J, Raza K, Sansom DM.

PLoS One. 2015 Jul 2;10(7):e0131539. doi: 10.1371/journal.pone.0131539. eCollection 2015.

19.

Tumor-Targeted Human T Cells Expressing CD28-Based Chimeric Antigen Receptors Circumvent CTLA-4 Inhibition.

Condomines M, Arnason J, Benjamin R, Gunset G, Plotkin J, Sadelain M.

PLoS One. 2015 Jun 25;10(6):e0130518. doi: 10.1371/journal.pone.0130518. eCollection 2015.

20.

Impaired T-Cell Function in B-Cell Lymphoma: A Direct Consequence of Events at the Immunological Synapse?

Nassef Kadry Naguib Roufaiel M, Wells JW, Steptoe RJ.

Front Immunol. 2015 Jun 2;6:258. doi: 10.3389/fimmu.2015.00258. eCollection 2015. Review.

Supplemental Content

Support Center